Healthcare Global Enterprises Limited (HCG) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated August 01, 2026 3 min read

Healthcare Global Enterprises (HCG) enters Q1 FY27 results following a period of significant balance sheet restructuring, including a successful rights issue and the divestment of its fertility business. Investors will be focused on whether the company can maintain its 15% revenue growth trajectory and deliver the targeted 100 bps margin expansion amidst ongoing regulatory scrutiny at its KR Unit.

Quick Details

Results date	August 06, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 652.30 Cr
Previous quarter PAT	Rs. 34.10 Cr
Previous quarter EBITDA margin	19.2%
Net debt (latest quarter)	Rs. 338.7 Cr
Market cap	Rs. 10021.16 Cr
CMP	Rs. 671.2

Healthcare Global Enterprises Limited Q1 Results Date and Time

The board meeting is scheduled for August 06, 2026, to approve the Q1 FY27 financial results.

The earnings call is scheduled for August 07, 2026, at 2:00 PM IST.

What to expect from Healthcare Global Enterprises Limited's Q1 FY27 results

HCG's revenue growth is expected to remain in-line with its 14-15% medium-term guidance, though reported figures will face a ~Rs. 15 Cr headwind due to the BACC fertility divestment closed on June 29, 2026. Margin expansion is likely to be a key theme, with management targeting 100 bps of improvement in FY27 from a base of 18.5% in FY26, supported by improved payor mix and operating leverage on existing centers. The balance sheet has been strengthened by the Rs. 424.68 Cr rights issue, which should provide a tailwind to profitability by lowering finance costs compared to the Rs. 176.57 Cr interest expense incurred in FY26. While the CDSCO suspension of the KR Unit Ethics Committee remains a regulatory overhang, the company has assessed no significant financial impact on its core oncology operations.

Key Things To Watch

Performance vs Guidance Tracking: Tracking HCG's progress against its medium-term financial and operational targets.

Revenue growth: 15%+ CAGR target vs 14.5% FY26 actual
EBITDA margin: 21-22% target by FY28 vs 18.5% FY26 actual
ROCE: 20% target by FY30 vs 14.0% FY26 actual

Strategic Capex and Expansion: Monitoring the deployment of capital from the recent rights issue and progress on new facilities.

Hebbal hospital construction status following the Rs. 129 Cr investment announcement
Deployment update on the Rs. 424.68 Cr proceeds from the May 2026 rights issue
Progress on 200+ bed additions across Cuttack, Ranchi, Vizag, and Bhavnagar

Operational and Regulatory Updates: Key non-financial factors impacting the quarterly narrative.

Resolution status of the 24-month CDSCO suspension of the KR Unit Ethics Committee
Like-for-like organic revenue growth excluding the divested fertility business
Recovery of volumes in Andhra Pradesh centers following the Q3 FY26 strike impact

Frequently Asked Questions

How did the BACC fertility divestment impact HCG's financials?

The divestment closed on June 29, 2026, for a total consideration of Rs. 37.64 Cr. It removes a business that contributed Rs. 60.45 Cr in FY26 revenue but was only marginally above break-even.

What is the status of HCG's leverage after the rights issue?

HCG reduced its net debt from Rs. 631.7 Cr in FY25 to Rs. 338.7 Cr by the end of FY26. The Rs. 424.68 Cr rights issue further deleverages the balance sheet, providing flexibility for growth capex.

Is HCG's revenue growth on track with its guidance?

HCG reaffirmed its 15% medium-term revenue growth guidance as of May 20, 2026. The company achieved 14.5% revenue growth in FY26, effectively matching the floor of its target band.